Seres Therapeutics announces FDA approval of VOWST for C. diff prevention and $250M Oaktree credit facility

Seres Therapeutics, Inc.

FDA approved VOWST (fecal microbiota spores) to prevent recurrent C. difficile infection; launch expected June 2023.
$125M milestone payment due from Nestlé under joint commercialization agreement upon approval.
Entered $250M Oaktree credit facility; initial $110M tranche funded, net proceeds ~$50M after repaying Hercules debt.
Issued warrants to lenders for 647,589 shares at $6.69/share; additional warrants tied to future tranches.
Preliminary cash and equivalents ~$107M as of March 31, 2023.

item 1.01 item 2.02 item 2.03 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Seres Therapeutics, Inc. entered into Credit Agreement with Oaktree Fund Administration, LLC, as administrative agent, and the lenders from time to time party thereto valued at $250 million (effective 2023-04-27).

Action: entry
Agreement: credit facility
Counterparty: Oaktree Fund Administration, LLC, as administrative agent, and the lenders from time to time party thereto
Value: $250 million
Effective: 2023-04-27

Exact text from the filing

On April 27, 2023 (the “Closing Date”), Seres Therapeutics, Inc., a Delaware corporation (the “Company”) entered into a Credit Agreement and Guaranty (the “Credit Agreement”), among the Company, the subsidiary guarantors from time to time party thereto, the lenders from time to time party thereto (the “Lenders”), and Oaktree Fund Administration, LLC, in its capacity as administrative agent for the Lenders (in such capacity, the “Agent”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-120045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.